COVID-19 trials registries data warehouse

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005801-14/DE

Janssen Research & Development - Clinical Registry Group

ClinicalTrialsEU@its.jnj.com

2020-12-23

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

1.Participant is 18 to 55 years of age, inclusive, on the day of signing the ICF. 2.Participant must have a BMI <35.0 kg/m2. 3.Participant must be healthy, in the investigator’s clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. Participant may have underlying illnesses, as long as the symptoms and signs are medically controlled and not considered to be comorbidities related to an increased risk of severe COVID-19 , except for smoking, which is allowed. If on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participant will be included on the basis of physical examination, medical history, and vital signs. 4.Contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies. 5.Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine.

1.Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature ≥38.0ºC (100.4°F) within 24 hours prior to the planned first dose of study vaccine, randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor. 2.Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence). 3.Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine). 4.Participant has abnormal function of the immune system resulting from: a.Clinical conditions (eg, autoimmune disease, potential immune mediated disease or known or suspected immunodeficiency, chronic kidney disease [with dialysis]) expected to have an impact on the immune response of the study vaccine. Participants with clinical conditions stable under non-immunomodulator treatment eg, autoimmune thyroiditis, autoimmune inflammatory rheumatic disease such as rheumatoid arthritis) may be enrolled at the discretion of the investigator. Non-immunomodulator treatment is allowed as well as steroids at a non-immunosuppressive dose or route of administration. b.Chronic or recurrent use of systemic corticosteroids within 6 months before administration of study vaccine and during the study. Note: Ocular, topical or inhaled steroids are allowed. c.Administration of antineoplastic and immunomodulating agents or radiotherapy within 6 months before administration of study vaccine and during the study. 5.Participant has a history of any neurological disorders or seizures including Guillain-Barré syndrome, with the exception of febrile seizures during childhood. 6.Participant has a history of chronic urticaria (recurrent hives), eczema or adult atopic dermatitis. 7.Participant received treatment with immunoglobulins in the 3 months or exogenous blood products (autologous blood transfusions are not exclusionary) in the 4 months before the planned administration of the first dose of study vaccine or has any plans to receive such treatment during the study. 8.Participant received or plans to receive: a.Licensed live attenuated vaccines – within 28 days before or after planned administration of the first or subsequent study vaccinations b.Other licensed (not live) vaccines – within 14 days before or after planned administration of the first or subsequent study vaccinations. 9.Participant received an investigational drug (including investigational drugs for prophylaxis of COVID-19) or used an invasive investigational medical device within 30 days or received investigational Ig or monoclonal antibodies within 3 months, or received convalescent serum for COVID-19 treatment within 4 months or received an investigational vaccine within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study. 10.Participant is a woman who is pregnant or planning to become pregnant within 3 months after the last dose of study vaccine. 11.Participant has a history of an underlying clinically significant acute or chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments. 12.Participant had surgery requiring hospitalization (defined as inpatient stay for longer than 24 hours or overnight stay), within 12 weeks before vaccination, or will not have fully recovered from surgery requiring hospitalization, or has surgery requiring hospitalization planned during the time the participant is expected to participate in the study or within 6 months after the last dose of study vaccine administration. 13.Participant has a contraindication to IM injections and blood draws eg, bleeding disorders. 14.Participant has chronic active hepatitis B or hepatitis C infection per medical history. 15.History of capillary leak syndrome. 16. History of TTS or heparin-induced thrombocytopenia and thrombosis (HITT).

6

Janssen Vaccines & Prevention B.V.

18

65

Brazil;South Africa;United States;Germany;Netherlands

Healthy volunteers

N/A

250

Main study: •Binding antibody concentrations to SARS CoV-2 S protein as measured by ELISA 28 days after vaccination •NI will be demonstrated in terms of humoral immune response expressed by the GMCs of S-ELISA, 28 days post-dose 1, using a NI margin of 2/3 for the GMC ratio (GMC 9x10^10 vp, 7x10^10 vp, 3.5x10^10 vp, 2.5x10^10 vp, or 1.25x10^10 vp/GMC 5x10^10 vp) •Binding antibody concentrations to SARS CoV-2 S protein as measured by ELISA 14 days after vaccination 2 •NI will be demonstrated in terms of humoral immune response expressed by the GMCs of S-ELISA, 14 days post-dose 2 (9x10^10 vp, 7x10^10 vp, 3.5x10^10 vp, 2.5x10^10 vp, or 1.25x10^10 vp) and 28 days post-dose 1 or 14 days post-dose 2 (5x10^10 vp), using a NI margin of 2/3 for the GMC ratio (GMC 9x10^10 vp, 7x10^10 vp, 3.5x10^10 vp, 2.5x10^10 vp, or 1.25x10^10 vp/GMC 5x10^10 vp)

Declared number of arm (6.0) differs from found arms (1.0)

Phase 3

[{"arm_notes": "New Type treatment : Not available", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "New Type treatment : Not available", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "New Type treatment : Not available", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "New Type treatment : Not available", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "New Type treatment : Not available", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "New Type treatment : Not available", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]